How antipsychotics work-from receptors to reality.
How does a small molecule blocking a few receptors change a patients' passionately held paranoid belief that the FBI is out to get him? To address this central puzzle of antipsychotic action, we review a framework linking dopamine neurochemistry to psychosis, and then link this framework to the mechanism of action of antipsychotics. Normal dopamine transmission has a role in predicting novel rewards and in marking and responding to motivationally salient stimuli. Abnormal dopamine transmission alters these processes and results in an aberrant sense of novelty and inappropriate assignment of salience leading to the experience of psychosis. Antipsychotics improve psychosis by diminishing this abnormal transmission by blocking the dopamine D2/3 receptor (not D1 or D4), and although several brain regions may be involved, it is suggested that the ventral striatal regions (analog of the nucleus accumbens in animals) may have a particularly critical role. Contrary to popular belief, the antipsychotic effect is not delayed in its onset, but starts within the first few days. There is more improvement in the first 2 weeks, than in any subsequent 2-week period thereafter. However, a simple organic molecule cannot target the complex phenomenology of the individual psychotic experience. Antipsychotics diminish dopamine transmission and thereby dampen the salience of the pre-occupying symptoms. Therefore, in the initial stage of an antipsychotic response, the patients experience a detachment from symptoms, a relegation of the delusions and hallucinations to the back of their minds, rather than a complete erasure of the symptoms. Only with time, and only in some, via the mediation of new learning and plasticity, is there a complete resolution of symptoms. The implications of these findings for clinical care, animal models, future target discovery and drug development are discussed.
Centre for Addiction and Mental Health, Toronto, Canada M5S 1A1; University of Toronto, Toronto, Canada. shitij_kapur@camh.net
Shitij
S
Kapur
Ofer
O
Agid
Romina
R
Mizrahi
Ming
M
Li
D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D018492:Dopamine Antagonists / Q000627:therapeutic use; D004358:Drug Therapy / Q000379:methods / Q000639:trends; D006801:Humans; D008960:Models, Psychological; D011618:Psychotic Disorders / Q000145:classification / Q000188:drug therapy*; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D011954:Receptors, Dopamine